As a leading cardiothoracic surgeon and a pioneer in cardiothoracic research, Dr. Rob perfected the latest procedures curing patients through surgical procedures as well as performing research to develop new operations, optimize recovery, and improve post-operative care. About 5 years ago, Dr. Rob retired from his surgical career to transition from thoracic surgery to a doctor committed to improving the baby boomer’s quality of life.
He continues to be board certified in General Surgery and Thoracic Surgery. He is certified by the American Academy of Anti-aging Medicine.* He is a fellow of the American College of Surgeons, and has three times received “America’s Top Doctor Award” in cardiothoracic surgery.
Today, he is fully devoted to the quality of life of his patients in such a way that their next visit will be at the office, not the operating table. “Don’t wait until it is too late” takes on a different meaning in medicine His practice has evolved to meet the needs of patients as well as the changing face of practicing medicine and preventative healthcare.
He was cited in 3 Suzanne Somers’ books, Ageless: The Naked Truth About Bioidentical Hormones, Breakthroughs: Eight Steps To Wellness, and Knock-out as a doctor she recommends for his expertise. Dedicated to healthy living, Dr. Rob is also a three-time Ironman, avid runner, and has completed over 20 marathons. He is happily married and the proud father of an up and coming athlete.
He is the founder of the Andlos Institute for Preventative Health Care and the creator of Stop-It™, a revolutionary, all natural herbal lozenge that stops sugar cravings. Read Full Details Below Dr. Rob received his BS degree cum laude, double majoring in Chemistry and Biology from Valparaiso University, and his MD degree from Wright State School of Medicine graduating in the top 15%.
He participated in cardiovascular research at Harvard University, and published extensively in burn metabolism during his medical school and surgical training. His postgrad training was in General Surgery at the University of Florida where Dr. Rob received numerous research awards and the coveted Woodward Surgical award (the top surgical resident award.)
He completed his cardiothoracic surgical training at Shands Hospital, University of Florida in 1994, and developed a minimally invasive cardiac and thoracic surgical practice in Sarasota, Florida. He is a fellow of the American College of Surgeons, and has three times received “America’s Top Doctor Award” in cardiothoracic surgery.
The Consumer Research Council of America has recognized Dr. Rob Carlson as Top American Surgeon in the Guide to America’s Top Surgeons 2002-2003, and 2006-2007, and 2010 editions, as well as 2005 Physician of the Year by the NRCC, and recently the coveted Man of the Year in Medicine and Healthcare by the ABI.
Today, Dr. Rob continues to be board certified in General Surgery, in Thoracic Surgery, and through the American Academy of Anti-aging Medicine in Age Management Medicine. A leading cardiothoracic surgeon and a pioneer in cardiothoracic research, Dr. Rob has perfected the latest procedures curing patients through surgical procedures as well as performing research to develop new operations, optimize recovery, and improve post-operative care.
*The specialty recognition identified herein is from a private organization not affiliated with or recognized by the Florida Board of Medicine.
Dr. Rob Carlson (Full CV)
UNDERGRADUATE EDUCATION: Valparaiso University B.S. Biology/Chemistry Cum Laude, May 1979
Ohio State School of Dentistry Columbus, OH 1979-1982
Wright State School of Medicine Dayton, OH M.D., 1986- Graduated in top 15%
INTERNSHIP: University of Florida- Shands Hospital Gainesville, FL General Surgery, 1986-1987
RESIDENCY: University of Florida- Shands Hospital Gainesville, Fl General Surgery, 1987-1982 Woodward Award- Top Surgical Resident
FELLOWSHIP: University of Florida- Shands Hospital Gainesville, Fl Cardiothoracic Surgery, 1992-1994
LICENSURE: Florida – ME: 0051783 Diplomat of National Board of Medical Examiners: Successful Completion Parts I, II and III
CERTIFICATION: American Board of Surgery, 2/94
American Board of Thoracic Surgery, 6/2/95
Advanced Cardiac Life Support, 2/08
RECERTIFICATION: American Board of Surgery, 12/03
American Board of Thoracic Surgery, 12/03
FELLOW AMERICAN COLLEGE OF SURGEONS
EMPLOYMENT: Robert G. Carlson, MD, FACS, Andlos Institute of Age Management 2914 Bee Ridge Road Sarasota, FL 34239 (present)
Gulf Coast Heart and Lung Surgery 1762 Hawthorne Street, Suite 4 Sarasota, FL 34239
Cardiovascular Associates 1880 Arlington Street, Suite 103 Sarasota, FL 34239 (September 1996- September 1999)
- Recipient of the 1990 Resident Award for Outstanding Research from the Society for Surgery of the Alimentary tract
- Radiological Sciences Award; 1983, 1986
- American Heart Association Research Fellowship; 1983, 1985
- National Resident Research Award; University of Florida, 1991
- Top Surgical Resident University of Florida 1992, Edward Woodward Surgical Resident Award.
- “America’s Top Surgeons” 2002-2003 Edition. Guide to America’s Top Surgeons, Consumer Research Council of America
- 2005 Physician of the Year, NRCC award
- “America’s Top Doctors” 2006-2007 Edition. Guide to America’s Top Doctors, Castle Connolly Medical LTD.
- “America’s Top Surgeons” 2009-2010 Edition. Guide to America’s Top Surgeons, Castle Connolly Medical LTD.
- Man of the Year in Medicine & Healthcare 2010. American Biographical Institute.
CLINICAL APPOINTMENT:Department Chairman- Department of Surgery, Columbia Doctors Hospital 1997-1999
MEMBERSHIPS:American College of Surgeons Florida Medical Society Florida Society of Thoracic Surgeons American College of Phlebology
PRIVILEGES:Sarasota Memorial Hospital- Medical Staff (semi-retired(resigned-December 2008) Columbia Doctors Hospital- Medical Staff (semi-retired(resigned)
MEDICAL-LEGAL:Nationally recognized expert witness with testimony/case review in:
- West Virginia
- North Carolina
- South Carolina
- South Dakota
- Washington D.C.
PUBLICATIONS:1. Carlson RG, Morath MA, Finley RK, Jr., Miller SF, et al: Fluid retention during the first 48 hours as an indicator of burn survival. (Abstract) Proceedings of the American Burn Association 16:105, 1984.
2. Carlson RG, Miller SF, Finley RK, Jr., and Jones LM: The relationship of body surface area to fluid dynamics in severely burned patients. (Abstract) Clinical Research 33 (4): 927A, 1985.
3. Carlson RG, Miller SF, Finley RK, Jr., et al: Fluid retention and burn patient survival. (abstract ) Proceedings of the American Burn Association 18:6, 1986.
4. Carlson RG, Finley RK, Jr., Miller SK, et al: Fluid retention during the first 48 hours as an indicator of burn survival. J Trauma 26:840-843, 1986.
5. Carlson RG, Miller SF, Finley RK, Jr., Billett JM, et al: Fluid retention and burn patient survival. J Trauma 27: 127-135,1987.
6. Carlson RG, Bagwell CE, Talbert JL: Giant breast mass in an adolescent female. Contemporary Surgery 35: 75-77, 1989.
7. Carlson RG, Fegelman E, Finley RK, Jr., Miller, SF: Assessment of the total body water in burn patients using bioelectric impedance analysis. Submitted to the Journal of Burn Care and Rehabilitation
8. Carlson RG, Mayfield WR, Normann S, Alexander JA: Radiation associated valvular heart disease. Chest 545, 1991.
9. Hocking MP, Carlson RG, Courington KR, Bland KI: Altered motility and bacterial flora following “functional end-to-end anastomosis”. Surgery 108(2) : 384-392, 1990.
10. Carlson RG, Hocking MP, Courington KR, Sninsky CA, Vogel SB: Erythromycin enhances gastric emptying in Roux-en-Y dogs with delayed gastric emptying. AM J Surg 161:31-35, 1990.
11. Hocking MP, Carlson RG, Harrison WE, Sninsky Ca, Vogel SB; Radionuclide gastric emptying, gastric myoelectric activity and the effect of electrical pacing after gastric surgery. Surg Forum XLT: 125-127,1990.
12. Carlson RG, Hocking MP, Sninsky CA, Vogel SB: Erythromycin acts through a cholinergic pathway to improve canine delayed gastric emptying following vagotomy and Roux-en-Y antrectomy. J Surg Res 50: 494-498, 1991.
13. Hocking MP, Carlson RG, Vogel SB: Selective vagotomy does not prevent delayed gastric emptying and altered myoelectric activity following Roux-en-Y gastrojejunostomy. AM J Surg (submitted for publication).
14. Carlson RG, Schiro, JC, Hertz C: Complete Myocardial Revascularization Is Safe Using Off -Pump Techniques in High Risk Elderly Patients. Am College of Cardiology (submitted for publication).
15. Sidney F. Miller,a M.D., Robert G Carlson, M.D. ,b Elliott Fegelman, M.D., c Jose Quinones, M.D. d and Robert K. Finley, Jr., M.D. a Dayton, Ohio. A comparison of Total Body Water Analyses: Bioelectric Impedance analysis Versus the Tritiate Water Method. American Burn Association, 1999.
16. Carlson RG, Schiro JC, Hertz C: Off-pump Coronary Artery Bypass in Octogenarians. MICS Symposium, May 25-27, 2000. (Abstract presentation ).
17. Carlson RG, O’Brien DJ, Knauf, DG. Radiation Heart Disease. In J.Willis Hurst: New Types of Cardiovascular Diseases, New York, Igaku-Shoin, 1994, p 225-239.
PRESENTATIONS:1. Fluid retention during the first 48 hours as an indicator of burn survival. Presented at the 16th Annual American Burn Association Meeting, San Francisco, CA, March 1984.
2. The relationship of body surface area to fluid dynamics in severely burned patients. Presented at the Midwest Medical Student Research Forum, Dayton, OH. May 1985.
3. Fluid retention and burn patient survival. Presented at the 18th Annual American Burn Association Meeting, Chicago, IL. April 1986.
4. Fluid retention and burn patient survival. Poster session at the 72nd Annual Clinical Congress of the American College of Surgeons, New Orleans, LA. October 1986.
5. Impedance and titrated water determinations of total body water in severely burned patients. Presented at the American College of Surgeons, Committee of Trauma, Florida Chapter. November 1988.
6. Erythromycin enhances gastric emptying in Roux-Y dogs with severe gastroparesis. Presented at the Society of University Resident’s Program, Los Angeles, CA. February 1990.
7. Erythromycin enhances gastric emptying in Roux-Y dogs with severe delayed gastric emptying. Presented at the Society for Surgery of the Alimentary Tract, San Antonio, TX. May 1990.
8. Erythromycin acts through a cholinergic mechanism to improve delayed gastric emptying following vagotomy and Roux-Y antrectomy. Presented to the Association of Academic Surgery, November 1990.
9. Complete coronary artery revascularization using off-pump techniques in elderly patients. Presented at Utrecht Workshop. Universitair Medisch Centrum, Utrecht, Netherlands. September 4, 1999. 10. Protecting Your Heart with Proper Hormone Replacement Therapy. 4th Annual International Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies. Las Vegas, Nevada December 7-10, 2006.
CLINICAL RESEARCH:PRINCIPAL INVESTIGATOR
1. Aventis Trial HOE 642/3002. “A double- blind, placebo-controlled, multi-national trial to investigate the effect of IV treatment with the Na+/H+ exchange inhibitor cariporide (HOE642) on all-cause mortality and myocardial infarction in patients at risk of myocardial necrosis during and after coronary artery bypass graft (CABG) surgery”
2. PERFECT: Perma Flow CABG Trial. Possis Medical Inc. Perma Flow Synthetic PTFE Vascular Graft SMH IRB 96-CARD-21
3. A Phase III Randomized, Parallel, Double-Blind, Multi-Center, Placebo-Controlled Study of the Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery with Cardiopulmonary Bypass. Procter & Gamble Pharmaceuticals, Alexion Pharmaceuticals, Inc. Pexelizumab. PRIMO CABG Protocol #2000099.
4. A Multi-Center, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of 2 mg/kg bolus plus 24-hour 0.05 mh/kg/hr Infusion of Pexelizumab in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery with Cardiopulmonary Bypass. (Primo 2)Proctor & Gamble Pharmaceuticals, Alexion Pharmaceuticals, Inc- Pexelizumab. Primo 2 Coronary Artery Bypass High Risk Patients –Protocol Study CO-INVESTIGATOR 1. AVANT Immunotherapeutics, Inc. TP-10ACS-001.
A Study of the Safety and Efficacy of TP-10 (SCR1) In the Prevention of Post Cardiopulmonary Bypass Syndromes In Adults. 2. OXYGENT TM CPB I 1999 Alliance Pharmaceuticals Corp., Protocol #OXHT-017-INT. 3. PROTOCOL# CGT003-04 A Phase III, Multi-Center,Randomized,Double-Blind Placebo Controlled Trial Of EX-VIVO Treatment With CGT003 Of Coronary Vein Grafts In Patients Undergoing Coronary Artery Bypass Grafting Procedures. 4. A Phase 2 Randomized Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Soluble Complement Receptor Type 1 (TP 10) in Adult women Undergoing Cardiopulmonary Bypass Surgery.
5. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study To Evaluate The Cardioprotective Effects of MC-1 In Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery. Mend-CABG II, Medicure International Inc, Clinical Research Protocol # 06004